Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492.30207593
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.21338.26808342
   PubMed Web of Science ®Google Scholar
• Igawa S, Ono T, Kasajima M, et al. Impact of amrubicin monotherapy as second-line chemotherapy on outcomes in elderly patients with relapsed extensive-disease small-cell lung cancer. Cancer Manag Res. 2020;12:4911–4921. doi:10.2147/cmar.s255552.32606979
   PubMed Web of Science ®Google Scholar
• Tsoukalas N, Aravantinou-Fatorou E, Baxevanos P, et al. Advanced small cell lung cancer (SCLC): new challenges and new expectations. Ann Transl Med. 2018;6(8):145. doi:10.21037/atm.2018.03.31.29862234
   PubMed Web of Science ®Google Scholar
• Yang S, Zhang Z, Wang Q. Emerging therapies for small cell lung cancer. J Hematol Oncol. 2019;12(1):47. doi:10.1186/s13045-019-0736-3.31046803
   PubMed Web of Science ®Google Scholar
• Poirier JT, George J, Owonikoko TK, et al. New approaches to SCLC therapy: from the laboratory to the clinic. J Thorac Oncol. 2020;15(4):520–540. doi:10.1016/j.jtho.2020.01.016.32018053
   PubMed Web of Science ®Google Scholar
• Dómine M, Moran T, Isla D, et al. SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019). Clin Transl Oncol. 2020;22(2):245–255. doi:10.1007/s12094-020-02295-w.32040815
   PubMed Web of Science ®Google Scholar
• Ott PA, Elez E, Hiret S, et al. Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study. J Clin Oncol. 2017;35(34):3823–3829. doi:10.1200/jco.2017.72.5069.28813164
   PubMed Web of Science ®Google Scholar
• Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, Phase 1/2 trial. Lancet Oncol. 2016;17(7):883–895. doi:10.1016/s1470-2045(16)30098-5.27269741
   PubMed Web of Science ®Google Scholar
• Nowak-Sliwinska P, Alitalo K, Allen E, et al. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis. 2018;21(3):425–532. doi:10.1007/s10456-018-9613-x.29766399
   PubMed Web of Science ®Google Scholar
• Dowell JE, Amirkhan RH, Lai WS, et al. Survival in small cell lung cancer is independent of tumor expression of VEGF and COX-2. Anticancer Res. 2004;24(4):2367–2373.15330186
   PubMed Web of Science ®Google Scholar
• Lu H, Jiang Z. Advances in antiangiogenic treatment of small-cell lung cancer. Onco Targets Ther. 2017;10:353–359. doi:10.2147/ott.s119714.28138259
   PubMed Web of Science ®Google Scholar
• Tiseo M, Boni L, Ambrosio F, et al. Italian, multicenter, Phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer: the GOIRC-AIFA FARM6PMFJM trial. J Clin Oncol. 2017;35(12):1281–1287. doi:10.1200/jco.2016.69.4844.28135143
   PubMed Web of Science ®Google Scholar
• Li H, Zeng J, Jin X, et al. Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study. Cancer Chemother Pharmacol. 2019;83(6):1083–1090. doi:10.1007/s00280-019-03823-4.30937519
   PubMed Web of Science ®Google Scholar
• Ying Cheng QW, Kai L, Li K, et al. OA13.03 anlotinib as third-line or further-line treatment in relapsed SCLC: a multicentre, randomized, double-blind Phase 2 trial. J Thorac Oncol. 2018;13(10):S351–S352. doi:10.1016/j.jtho.2018.08.308.
   Web of Science ®Google Scholar
• Wang S, Zimmermann S, Parikh K, et al. Current diagnosis and management of small-cell lung cancer. Mayo Clin Proc. 2019;94(8):1599–1622. doi:10.1016/j.mayocp.2019.01.034.31378235
   PubMed Web of Science ®Google Scholar
• Wu D, Nie J, Hu W, et al. A Phase II study of anlotinib in 45 patients with relapsed small cell lung cancer. Int J Cancer. 2020. doi:10.1002/ijc.33161.
   Web of Science ®Google Scholar
• Chung HC, Piha-Paul SA, Lopez-Martin J, et al. Pembrolizumab after two or more lines of previous therapy in patients with recurrent or metastatic SCLC: results from the KEYNOTE-028 and KEYNOTE-158 studies. J Thorac Oncol. 2020;15(4):618–627. doi:10.1016/j.jtho.2019.12.109.31870883
   PubMed Web of Science ®Google Scholar
• Gitlitz BJ, Moon J, Glisson BS, et al. Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest oncology group (SWOG 0435) phase II trial. J Thorac Oncol. 2010;5(11):1835–1840. doi:10.1097/JTO.0b013e3181f0bd78.20881645
   PubMed Web of Science ®Google Scholar
• Schneider BJ, Gadgeel SM, Ramnath N, et al. Phase II trial of sunitinib maintenance therapy after platinum-based chemotherapy in patients with extensive-stage small cell lung cancer. J Thorac Oncol. 2011;6(6):1117–1120. doi:10.1097/JTO.0b013e31821529c3.21512407
   PubMed Web of Science ®Google Scholar
• Liu X, Qin S, Wang Z, et al. Correction to: early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol. 2018;11(1):5. doi:10.1186/s13045-017-0545-5.29316953
   PubMedGoogle Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026.19097774
   PubMed Web of Science ®Google Scholar
• Miller TP, Fisher BT, Getz KD, et al. Unintended consequences of evolution of the common terminology criteria for adverse events. Pediatr Blood Cancer. 2019;66(7):e27747. doi:10.1002/pbc.27747.30968531
   PubMed Web of Science ®Google Scholar
• Goodwin R, Ding K, Seymour L, et al. Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC clinical trials group study BR24. Ann Oncol. 2010;21(11):2220–2226. doi:10.1093/annonc/mdq221.20427348
   PubMed Web of Science ®Google Scholar
• Fukuda M, Soda H, Soejima Y, et al. A Phase I trial of carboplatin and etoposide for elderly (>or=75 year-old) patients with small-cell lung cancer. Cancer Chemother Pharmacol. 2006;58(5):601–606. doi:10.1007/s00280-006-0188-7.16463061
   PubMed Web of Science ®Google Scholar
• Yang Y, Sun N, Sun P, et al. Clinical characteristics and prognosis of elderly small cell lung cancer patients complicated with hyponatremia: a retrospective analysis. Anticancer Res. 2017;37(8):4681–4686. doi:10.21873/anticanres.11872.28739771
   PubMed Web of Science ®Google Scholar
• Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US food and drug administration. J Clin Oncol. 2004;22(22):4626–4631. doi:10.1200/jco.2004.02.175.15542812
   PubMed Web of Science ®Google Scholar
• Reck M, Horn L, Novello S, et al. Phase II study of roniciclib in combination with cisplatin/etoposide or carboplatin/etoposide as first-line therapy in patients with extensive-disease small cell lung cancer. J Thorac Oncol. 2019;14(4):701–711. doi:10.1016/j.jtho.2019.01.010.30677506
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi:10.1056/NEJMoa1809064.30280641
   PubMed Web of Science ®Google Scholar
• Garst J. Topotecan: an evolving option in the treatment of relapsed small cell lung cancer. Ther Clin Risk Manag. 2007;3(6):1087–1095.18516270
   PubMedGoogle Scholar
• de Jong WK, Ten Hacken NH, Groen HJ. Third-line chemotherapy for small cell lung cancer. Lung Cancer. 2006;52(3):339–342. doi:10.1016/j.lungcan.2006.02.005.16564112
   PubMed Web of Science ®Google Scholar
• Han B, Li K, Wang Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 Phase 3 randomized clinical trial. JAMA Oncol. 2018;4(11):1569–1575. doi:10.1001/jamaoncol.2018.3039.30098152
   PubMed Web of Science ®Google Scholar
• Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res. 2018;24(21):5233–5238. doi:10.1158/1078-0432.ccr-17-3766.29895706
   PubMed Web of Science ®Google Scholar
• Li J, Chen P, Dai CH, et al. Outcome and treatment in elderly patients with small cell lung cancer: a retrospective study. Geriatr Gerontol Int. 2009;9(2):172–182. doi:10.1111/j.1447-0594.2009.00525.x.19740361
   PubMed Web of Science ®Google Scholar
• Zhang K, Ma X, Gao H, et al. Efficacy and safety of anlotinib in advanced non-small cell lung cancer: a real-world study. Cancer Manag Res. 2020;12:3409–3417. doi:10.2147/cmar.s246000.32494205
   PubMed Web of Science ®Google Scholar
• Bremnes RM, Sundstrom S, Aasebø U, et al. The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer. 2003;39(3):303–313. doi:10.1016/s0169-5002(02)00508-1.12609569
   PubMed Web of Science ®Google Scholar
• Liu JY, Zhu BR, Wang YD, et al. The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis. Int J Clin Oncol. 2020;25(6):1195–1205. doi:10.1007/s10147-020-01644-7.32215805
   PubMed Web of Science ®Google Scholar
• Chen D, Xu J, Zhao Y, et al. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib. J Cancer Res Clin Oncol. 2020;146(2):401–406. doi:10.1007/s00432-019-03064-1.31691871
   PubMed Web of Science ®Google Scholar
• Wang J, Ma JJ, Liu J, et al. Prevalence and risk factors of comorbidities among hypertensive patients in China. Int J Med Sci. 2017;14(3):201–212. doi:10.7150/ijms.16974.28367080
   PubMed Web of Science ®Google Scholar
• Fang SC, Huang W, Zhang YM, et al. Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib. Onco Targets Ther. 2019;12:985–992. doi:10.2147/ott.s189984.30774384
   PubMed Web of Science ®Google Scholar
• Liu X, Qin S, Wang Z, et al. Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study. J Hematol Oncol. 2017;10(1):153. doi:10.1186/s13045-017-0521-0.28870253
   PubMedGoogle Scholar
• Tang JR, Markham NE, Lin YJ, et al. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am J Physiol Lung Cell Mol Physiol. 2004;287(2):L344–351. doi:10.1152/ajplung.00291.2003.15064225
   PubMed Web of Science ®Google Scholar
• Fischer A, Wu S, Ho AL, et al. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs. 2013;31(3):787–797. doi:10.1007/s10637-013-9927-x.23345001
   PubMed Web of Science ®Google Scholar
• Lankhorst S, Kappers MH, van Esch JH, et al. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1. J Hypertens. 2013;31(3):444–454. doi:10.1097/HJH.0b013e32835c1d1b.23221987
   PubMed Web of Science ®Google Scholar
• Aparicio-Gallego G, Afonso-Afonso FJ, León-Mateos L, et al. Molecular basis of hypertension side effects induced by sunitinib. Anticancer Drugs. 2011;22(1):1–8. doi:10.1097/CAD.0b013e3283403806.20938340
   PubMed Web of Science ®Google Scholar